Lilly, Gilead, Amgen started at outperform by Bernstein
As for Lilly ( LLY ), Bernstein said its outperform rating “hinges on what they can do with the cash they generate from ...
Cautious Optimism: Amgen’s Uplizna Shows Promise but Limited Immediate Impact on Valuation
Analyst Mohit Bansal of Wells Fargo maintained a Hold rating on Amgen (AMGN – Research Report), retaining the price target of $335.00.
MedPage Today3d
Anti-CD19 Monoclonal Antibody Shows Positive Results in Myasthenia Gravis
"Inebilizumab is a humanized monoclonal antibody that causes targeted and sustained depletion of CD19-positive B cells, ...
Amgen Myasthenia Gravis Drug Meets Primary Goal in Phase 3 Trial
Amgen said it achieved positive results from a Phase 3 trial of its treatment for adults with generalized myasthenia gravis, a rare autoimmune disorder.
Amgen Reports Positive Phase 3 Data For Uplizna In Generalized Myasthenia Gravis
Tuesday announced positive topline data from the Phase 3 MINT study evaluating Uplizna for the treatment of adults ...
AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA® (INEBILIZUMAB-CDON) IN GENERALIZED MYASTHENIA GRAVIS (GMG) AT AANEM 2024
Amgen (NASDAQ:AMGN) today announced the presentation of positive top-line results from the Phase 3 MINT trial evaluating the ...
The Pharma Letter4d
Amgen to file for Uplizna approval in gMG
US biotech major Amgen (Nasdaq: AMGN) has further strengthened the growing evidence for the use of Uplizna (inebilizumab-cdon ...
Amgen downgraded at Truist on MariTide prospects for obesity
Amgen has downgraded Amgen from buy to hold saying that the potential for obesity asset MariTide is already included in the ...